Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
How long can Smith and Nephew stay independent at this MCap?? Never seen a more vulnerable FTSE 250+ share that's such a gem of a buy at this stage of the market cycle. Money should be pouring into healthcare and surgical companies and S&N is missing out as a result of a CEO who lacks sentiment, charisma and drive. Under a bigger umbrella and a BoD with the vision and resources to crystallize value here, S&N is worth a lot more than this. Let's see who steps up to the plate.....US, Middle or Far East??
I’d be interested in Stockready1s assessment now given this will not be £15 by the end of august now…
I sold at £1255 after Naths decision to sell his shares and it’s proven to be the right call.
Why oh why did the BoD pick Nath.??? His decision to sell shares within 30 days of his appointment has poisoned investor sentiment. To take a company like S&N from £13.25 To £10.50 in less than 5 months is an epic CEO failure. The company is sound, has impeccable provenance and trust from consultants and medical staff worldwide, and is in a high barrier to entry sector. The backlog of operations requiring S&N products is burgeoning. The lack of enthusiastic positivity in the face of adversity by Nath was tangible. Absolutely useless when a new CEO can't motivate everyone with his infectious enthusiasm....not. If there was ever a time for an opportunistic bid it is NOW. Cable rate favourable and tax breaks huge for US predator but I wouldn't rule out a bid from the Middle or Far East as the new Malaysian facility is up and running. Time for a fresh start with new CEO and dynamic board reshuffle or t/o. Period. Excellent British Company with a Muppet at the helm. Change urgently needed for charisma injection.
They vest and a certain percentage are taken to cover the tax upon vesting. I know how the scheme works. He still has all the vested stock. It’s all in the RNS.
If it doesn't close above it tomorrow, who knows where the new low will be!
Jimmybob I worked in companied which awarded shares but I didn't have to sell ALL and remain with 0 balance to pay all the full sale value on tax. If this would be true than Musk would have 0 shares in Tesla. He sold ALL his shares; he is the only CEO witch has no vested interest at all in the company.
Read the RNS relating to the sale. The awards were granted under the Global Share Plan 2010 on 23 May 2019. One third of the shares vested on 23 May 2020, a further third vested on 23 May 2021 and the final third vested on 23 May 2022. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. This is how these awards work you don’t have an option not to sell to cover the tax liabilities.
Jimmybob please explain, I do understand that he may have lost the options in the other company but this does not mean that he had to sell SN. He could have kept them isn't it?
GLA
CEO sale was forced the options in Leu to cover option from his previous company. CEO has a plan to turn around the Ortho business. Give him chance he is making the right noises.
China now bulk buying, further reducing margins.
Are sector margins sustainable in orthopaedics?, is what the
market may be questioning.
Not an over-reaction IMO. The price reflects the performance even though supplies are an issue for a lot of Companies dealing with China. Also am now in but would rather see the Co being taken over. Will recover as it always does but a takeover offer would be better for all.
This new CEO sold all his allocated shares on 23 May the SP tanked on the 3oth from 13 to 11 . How is it possible that a CEO don't have the skin in the game and behaves as a rat running from the sinking boat rather than a Capitan living the last.
This guy is incapable to articulate a vision and depresses the market with its own presence, he didn't manage to hold on jobs for longer than 2-3 years and was more of a manager rather than a CEO.
I hope he is on notice
I’m going with overreaction. Surely the weaknesses highlighted were reasonably self evident and transitory in nature. Too many short/medium/long term opportunities here to ignore. Great entrance price - I’m in.
Look at the fall in cash generation..
However, it's the margin outlook that
the market appears not to like
NB: This was when the share price was £13 not £10. Even more of a target now.
Oxford BioMedica PLC (LSE:OXB), Smith & Nephew PLC (LSE:SN) and Spire Healthcare Group Plc (LSE:SPI) are among UK midcap health-care companies "vulnerable” to takeovers from private-equity (PE) firms, investment bank RBC Group says.
The stocks trade below historical multiples and have under-geared balance sheets - making them ripe for "PE firms seemingly well-funded and large trade players having strong balance sheets, and in some cases post-COVID earnings holes to fill," according to the bank.
Trauma and orthopaedic equipment provider Smith & Nephew’s shares are trading “35% below their peak”, the bank said, partly due to the impact of Covid-19 on hospital activity, while its balance sheet is “only modestly geared at 1.6x EBITDA”.
RBC said a consortium of buyers might opt to divest the company's wound care business for a partial return, but with such a hefty price tag, the asset would be likely to come back to the public markets in future.
“A re-IPO could be the potential exit route for PE,” it said.
Got my short term calls wrong on this one, that said, from the estimates i personally expected today, the figures themselves are actually better than i expected. (marginally mind) Very downbeat statement does little to assist positive thinking for the next 6-12 months though, this is what im most disappointed in.
Will ride this as i still fully believe in the business. Imagine there will be a small fight back tomorrow before continuing to be bumpy for a while. Reality in my eyes is that SN. is still very cheap. Takeover potential is definitely high now at this price.
Tim V, Looks like your portfolio manager played a blinder...I'd keep hold of them!
It's times like these I wished I'd someone like them to listen to when your heart is shouting louder than your head:-)
Context was poor here,insider dumping when he was just hot in his seat and well ready to kitchen sink the results/outlook.
£10.50 is critical here as if it breaks then further weakness is probable.
Its hard to make a case for a short term rally that wont get sold.
Long term a good investment,short term best to hold what one has and care warranted on adding until/if the £10.50 holds.
Best of luck.
of your calls on SN. ?, given the price at the time of this post
is Under £10.80 at the time of this post..
All those Buys you gave this ...
Agreed...
Results are the same as H1 2021 and would have been better if not for China lockdowns.
The balance sheet is much improved with debt paid down and Debt:Equity now <1 which is excellent.
Predators will be eyeing this with great interest. Multi year lows.
Beached Whale sums the current market up well.......
Not a Bear to be seen yet......
Guys, after a big fail, better to wait 3/4 days. It will go lower, unless you're day trading them
....
Ripley94......good one, took a few to trade, slightly more ........paid 1067p, alot of bargains around today.......only for the short term though , energy bill rising...... Gla